Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism — Stella

Home/Secondary Hyperparathyroidism, Chronic Kidney Disease/

View on ClinicalTrials.gov

Recruiting

Back to Secondary Hyperparathyroidism, Chronic Kidney Disease trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

Zhongshan Hospital, Shanghai, Shanghai Municipality

Key details

Phase

Large-scale testing

Sponsor

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Enrollment target

~424 participants

Started

September 2025

Primary completion

November 2026

Age range

18 Years and older

Last updated October 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.